X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA FULFORD INDIA ALEMBIC PHARMA/
FULFORD INDIA
 
P/E (TTM) x 28.9 398.8 7.3% View Chart
P/BV x 6.6 6.2 106.1% View Chart
Dividend Yield % 0.7 0.1 843.3%  

Financials

 ALEMBIC PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
FULFORD INDIA
Mar-14
ALEMBIC PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs792942 84.0%   
Low Rs443450 98.4%   
Sales per share (Unadj.) Rs167.0691.4 24.2%  
Earnings per share (Unadj.) Rs38.211.5 333.0%  
Cash flow per share (Unadj.) Rs42.015.4 273.4%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.3 225.5%  
Book value per share (Unadj.) Rs84.9380.0 22.3%  
Shares outstanding (eoy) m188.523.90 4,833.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.0 367.2%   
Avg P/E ratio x16.260.7 26.6%  
P/CF ratio (eoy) x14.745.3 32.4%  
Price / Book Value ratio x7.31.8 397.0%  
Dividend payout %10.517.4 60.1%   
Avg Mkt Cap Rs m116,3832,714 4,287.6%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m4,214505 834.4%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m31,4872,696 1,167.7%  
Other income Rs m55125 43.9%   
Total revenues Rs m31,5422,822 1,117.8%   
Gross profit Rs m10,060-46 -21,680.6%  
Depreciation Rs m72215 4,750.7%   
Interest Rs m3710 387.4%   
Profit before tax Rs m9,35654 17,230.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,16010 22,502.1%   
Profit after tax Rs m7,19445 16,094.6%  
Gross profit margin %31.9-1.7 -1,856.6%  
Effective tax rate %23.117.7 130.6%   
Net profit margin %22.81.7 1,378.3%  
BALANCE SHEET DATA
Current assets Rs m15,0661,738 866.7%   
Current liabilities Rs m7,674545 1,408.9%   
Net working cap to sales %23.544.3 53.0%  
Current ratio x2.03.2 61.5%  
Inventory Days Days6748 138.2%  
Debtors Days Days414 943.8%  
Net fixed assets Rs m8,23712 69,222.3%   
Share capital Rs m37739 966.7%   
"Free" reserves Rs m15,4161,443 1,068.4%   
Net worth Rs m16,0051,482 1,080.0%   
Long term debt Rs m00-   
Total assets Rs m24,5942,077 1,184.3%  
Interest coverage x255.26.7 3,800.6%   
Debt to equity ratio x00-  
Sales to assets ratio x1.31.3 98.6%   
Return on assets %29.42.6 1,126.6%  
Return on equity %44.93.0 1,490.3%  
Return on capital %58.74.3 1,363.0%  
Exports to sales %55.70-   
Imports to sales %10.424.5 42.6%   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283659 498.0%   
Fx inflow Rs m17,81117 103,549.4%   
Fx outflow Rs m5,318673 790.0%   
Net fx Rs m12,493-656 -1,904.5%   
CASH FLOW
From Operations Rs m9,30490 10,337.7%  
From Investments Rs m-3,105105 -2,968.3%  
From Financial Activity Rs m-1,959-14 13,894.3%  
Net Cashflow Rs m4,240181 2,349.0%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 3.8 76.3%  
FIIs % 9.1 0.1 9,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.2 65.6%  
Shareholders   49,328 4,783 1,031.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   PANACEA BIOTECH  BIOCON LTD  J.B.CHEMICALS  SUVEN LIFE  WYETH LTD  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS